George Dimopoulos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4207694/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host and Microbe, 2020, 27, 992-1000.e3.	11.0	1,746
2	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current Â-Lactam Antibiotic Doses Sufficient for Critically III Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	5.8	843
3	Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. European Respiratory Journal, 2016, 47, 45-68.	6.7	654
4	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. Intensive Care Medicine, 2020, 46, 1127-1153.	8.2	504
5	A Clinical Algorithm to Diagnose Invasive Pulmonary Aspergillosis in Critically Ill Patients. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 56-64.	5.6	497
6	Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Critical Care, 2015, 19, 7.	5.8	310
7	Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis. Cell Host and Microbe, 2020, 28, 117-123.e1.	11.0	210
8	Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. International Journal of Antimicrobial Agents, 2014, 43, 52-59.	2.5	188
9	Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 2011, 66, i5-i14.	3.0	178
10	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases, The 2021 21 e246-e257	9.1	167
11	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Medicine, 2015, 41, 1601-1610.	8.2	165
12	Candida Albicans Versus Non-Albicans Intensive Care Unit-Acquired Bloodstream Infections: Differences in Risk Factors and Outcome. Anesthesia and Analgesia, 2008, 106, 523-529.	2.2	163
13	Attributable mortality of <i>Stenotrophomonas maltophilia</i> infections: a systematic review of the literature. Future Microbiology, 2009, 4, 1103-1109.	2.0	152
14	Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Medicine, 2016, 42, 1958-1969.	8.2	151
15	Prevalence, Risk Factors, and Mortality for Ventilator-Associated Pneumonia in Middle-Aged, Old, and Very Old Critically III Patients*. Critical Care Medicine, 2014, 42, 601-609.	0.9	150
16	Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive Care Medicine, 2014, 40, 1340-1351.	8.2	147
17	Low-Dose Vasopressin in the Treatment of Septic Shock in Sheep. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 481-486.	5.6	140
18	Centers for Disease Control and Prevention guidelines for preventing central venous catheter-related infection: Results of a knowledge test among 3405 European intensive care nurses*. Critical Care Medicine, 2009, 37, 320-323.	0.9	138

#	Article	IF	CITATIONS
19	A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia. Chest, 2017, 151, 1239-1246.	0.8	136
20	Management of KPC-producing Klebsiella pneumoniae infections. Clinical Microbiology and Infection, 2018, 24, 133-144.	6.0	136
21	Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Medicine, 2015, 41, 2057-2075.	8.2	133
22	Short- versus Long-Course Antibacterial Therapy for Community-Acquired Pneumonia. Drugs, 2008, 68, 1841-1854.	10.9	132
23	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy 2016, 71, 196-207	3.0	129
24	Short- vs Long-Duration Antibiotic Regimens for Ventilator-Associated Pneumonia. Chest, 2013, 144, 1759-1767.	0.8	127
25	ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Medicine, 2019, 45, 789-805.	8.2	127
26	Impact of patient position on the incidence of ventilator-associated pneumonia: A meta-analysis of randomized controlled trials. Journal of Critical Care, 2009, 24, 515-522.	2.2	125
27	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Medicine, 2017, 43, 1225-1238.	8.2	123
28	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care, 2019, 23, 219.	5.8	123
29	Community-acquired Stenotrophomonas maltophilia infections: a systematic review. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 719-730.	2.9	116
30	Invasive Fungal Infections in the ICU: How to Approach, How to Treat. Molecules, 2014, 19, 1085-1119.	3.8	116
31	Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Medicine, 2013, 39, 672-681.	8.2	114
32	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Critical Care, 2015, 19, 33.	5.8	108
33	An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Medicine, 2012, 38, 940-949.	8.2	106
34	Heteroresistance: a concern of increasing clinical significance?. Clinical Microbiology and Infection, 2008, 14, 101-104.	6.0	105
35	Validation of the new Sepsis-3 definitions: proposal for improvement in early risk identification. Clinical Microbiology and Infection, 2017, 23, 104-109.	6.0	105
36	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Medicine, 2017, 43, 1187-1197.	8.2	103

#	Article	IF	CITATIONS
37	Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeSâ€; a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Medicine, 2019, 45, 1703-1717.	8.2	103
38	Evidence-based guidelines for the prevention of ventilator-associated pneumonia: results of a knowledge test among European intensive care nurses. Journal of Hospital Infection, 2008, 70, 180-185.	2.9	102
39	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Medicine, 2018, 44, 189-196.	8.2	101
40	Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials. Lancet Infectious Diseases, The, 2008, 8, 543-552.	9.1	94
41	Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Critical Care, 2012, 16, R149.	5.8	94
42	Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. International Journal of Antimicrobial Agents, 2009, 33, 394-404.	2.5	87
43	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Critical Care, 2014, 18, R99.	5.8	87
44	Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clinical Microbiology and Infection, 2011, 17, E9-E11.	6.0	86
45	Post mortem examination in the intensive care unit: still useful?. Intensive Care Medicine, 2004, 30, 2080-2085.	8.2	85
46	Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 439-443.	2.9	80
47	Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 377-384.	2.9	74
48	Potential risk factors for infection with Candida spp. in critically ill patients. Clinical Microbiology and Infection, 2004, 10, 550-555.	6.0	72
49	A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections. Clinical Infectious Diseases, 2015, 61, civ707.	5.8	72
50	Early Switch to Oral Treatment in Patients with Moderate to Severe Community-Acquired Pneumonia. Drugs, 2008, 68, 2469-2481.	10.9	70
51	Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus. Shock, 2020, 54, 633-637.	2.1	68
52	Ventilator-Associated Pneumonia. Chest, 2008, 133, 625-632.	0.8	67
53	Viral epidemiology of acute exacerbations of chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics, 2012, 25, 12-18.	2.6	67
54	Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. Journal of Infection, 2011, 63, 344-350.	3.3	65

#	Article	IF	CITATIONS
55	What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. International Journal of Antimicrobial Agents, 2013, 42, 289-293.	2.5	63
56	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 6471-6476.	3.2	59
57	Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Critical Care, 2016, 20, 53.	5.8	59
58	Invasive aspergillosis in the intensive care unit. Annals of the New York Academy of Sciences, 2012, 1272, 31-39.	3.8	58
59	Treatment of invasive candidiasis in the elderly: a review. Clinical Interventions in Aging, 2013, 8, 1199.	2.9	58
60	Comparison of First-Line With Second-Line Antibiotics for Acute Exacerbations of Chronic Bronchitis. Chest, 2007, 132, 447-455.	0.8	57
61	Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. Journal of Antimicrobial Chemotherapy, 2008, 62, 442-450.	3.0	56
62	Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. International Journal of Antimicrobial Agents, 2009, 33, 554.e1-554.e7.	2.5	55
63	Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Medicine, 2020, 46, 1404-1417.	8.2	54
64	Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic) Tj ETQq0 0 C Care, 2019, 23, 383.) rgBT /Ove 5.8	erlock 10 Tf 50 53
65	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <scp>FUN</scp> gal infections Definitions in <scp>ICU</scp> patients (<scp>FUNDICU</scp>) project. Mycoses, 2019, 62, 310-319.	4.0	53
66	Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity. Diabetes Research and Clinical Practice, 2020, 166, 108331.	2.8	53
67	Pandemic A(H1N1) 2009 influenza: review of the Southern Hemisphere experience. Epidemiology and Infection, 2011, 139, 27-40.	2.1	52
68	A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA). Journal of Fungi (Basel, Switzerland), 2021, 7, 1067.	3.5	52
69	Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. European Respiratory Journal, 2007, 29, 1127-1137.	6.7	51
70	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Medicine, 2017, 43, 509-518.	8.2	51
71	Clinical Significance of the Pharmacokinetic and Pharmacodynamic Characteristics of Tigecycline. Current Drug Metabolism, 2009, 10, 13-21.	1.2	49
72	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. International Journal of Antimicrobial Agents, 2014, 43, 423-430.	2.5	48

#	Article	IF	CITATIONS
73	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infectious Diseases, 2012, 12, 152.	2.9	47
74	Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. Critical Care, 2005, 9, R508.	5.8	46
75	Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. Journal of Critical Care, 2011, 26, 331.e1-331.e7.	2.2	44
76	Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clinical Microbiology and Infection, 2012, 18, 680-687.	6.0	44
77	Polymicrobial bloodstream infections: Epidemiology and impact on mortality. Journal of Global Antimicrobial Resistance, 2013, 1, 207-212.	2.2	43
78	Fluoroquinolones compared with Â-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. Cmaj, 2008, 178, 845-854.	2.0	41
79	Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future Microbiology, 2014, 9, 1053-1069.	2.0	41
80	Chemotherapy-induced neutropenia in lung cancer patients: The role of antibiotic prophylaxis. Cancer Letters, 2011, 313, 9-14.	7.2	40
81	Kinetics of circulating fetuin-A may predict mortality independently from adiponectin, high molecular weight adiponectin and prognostic factors in critically ill patients with sepsis: A prospective study. Journal of Critical Care, 2017, 41, 78-85.	2.2	40
82	COVID-19-Associated Pulmonary Aspergillosis (CAPA). Journal of Intensive Medicine, 2021, 1, 71-80.	2.1	40
83	Are infections due to resistant pathogens associated with a worse outcome in critically ill patients?. Journal of Infection, 2003, 47, 307-316.	3.3	38
84	Controversies in the management of the critically ill: the role of probiotics. International Journal of Antimicrobial Agents, 2013, 42, S41-S44.	2.5	37
85	Critically Ill Elderly Adults with Infection: Analysis of the Extended Prevalence of Infection in Intensive Care Study. Journal of the American Geriatrics Society, 2013, 61, 2065-2071.	2.6	34
86	Optimal Adrenergic Support in Septic Shock Due to Peritonitis. Anesthesiology, 2003, 98, 888-896.	2.5	33
87	Gut mucosal damage during endotoxic shock is due to mechanisms other than gut ischemia. Journal of Applied Physiology, 2003, 95, 2047-2054.	2.5	33
88	Inhaled corticosteroids and Aspergillus fumigatus isolation in cystic fibrosis. Medical Mycology, 2014, 52, 715-722.	0.7	33
89	AME evidence series 001—The Society for Translational Medicine: clinical practice guidelines for diagnosis and early identification of sepsis in the hospital. Journal of Thoracic Disease, 2016, 8, 2654-2665.	1.4	33
90	Is Candida really a threat in the ICU?. Current Opinion in Critical Care, 2008, 14, 600-604.	3.2	32

#	Article	IF	CITATIONS
91	Diagnosis and management of temperature abnormality in ICUs: a EUROBACT investigators' survey. Critical Care, 2013, 17, R289.	5.8	32
92	How to treat fungal infections in ICU patients. BMC Infectious Diseases, 2015, 15, 205.	2.9	32
93	Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis: A prospective observational study. Cytokine, 2019, 119, 62-70.	3.2	30
94	Cerebral aspergillosis in adult critically ill patients: a descriptive report of 10 patients from the AspICU cohort. International Journal of Antimicrobial Agents, 2014, 43, 165-169.	2.5	27
95	A 10-Year Survey of Antifungal Susceptibility of Candidemia Isolates from Intensive Care Unit Patients in Greece. Antimicrobial Agents and Chemotherapy, 2009, 53, 1242-1244.	3.2	25
96	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. Clinical Infectious Diseases, 2019, 69, 1912-1918.	5.8	24
97	The haemostatic profile in critically ill COVID-19 patients receiving therapeutic anticoagulant therapy. Medicine (United States), 2020, 99, e23365.	1.0	24
98	Blood Warming during Hemofiltration Can Improve Hemodynamics and Outcome in Ovine Septic Shock. Anesthesiology, 2006, 104, 1216-1222.	2.5	23
99	How to select an antifungal agent in critically ill patients. Journal of Critical Care, 2013, 28, 717-727.	2.2	23
100	A validated method for the quantification of fosfomycin on dried plasma spots by HPLC–MS/MS: Application to a pilot pharmacokinetic study in humans. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 509-514.	2.8	23
101	The Value of E-Learning for the Prevention of Healthcare-Associated Infections. Infection Control and Hospital Epidemiology, 2016, 37, 1052-1059.	1.8	22
102	Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges. Expert Review of Anti-Infective Therapy, 2017, 15, 211-229.	4.4	22
103	Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRIs project. ERJ Open Research, 2017, 3, 00092-2017.	2.6	22
104	New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia. Annals of Translational Medicine, 2018, 6, 423-423.	1.7	22
105	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 723-730.	1.4	22
106	ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically III COVID-19 Patients. Journal of Innate Immunity, 2022, 14, 218-228.	3.8	21
107	H1N1v influenza vaccine in Greek medical students. European Journal of Public Health, 2011, 21, 329-332.	0.3	20
108	Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial. Trials, 2015, 16, 102.	1.6	17

#	Article	IF	CITATIONS
109	Which algorithm diagnoses invasive pulmonary aspergillosis best in ICU patients with COPD?. European Respiratory Journal, 2017, 50, 1700532.	6.7	17
110	Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?. Expert Review of Anti-Infective Therapy, 2019, 17, 201-210.	4.4	17
111	Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group. Infectious Diseases and Therapy, 2020, 9, 407-416.	4.0	17
112	Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital. Infectious Diseases and Therapy, 2021, 10, 1779-1792.	4.0	17
113	Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis. International Journal of Antimicrobial Agents, 2012, 40, 521-526.	2.5	16
114	Elderly versus nonelderly patients with invasive aspergillosis in the ICU: a comparison and risk factor analysis for mortality from the AspICU cohort. Medical Mycology, 2018, 56, 668-678.	0.7	16
115	Approach to the Febrile Patient in the ICU. Infectious Disease Clinics of North America, 2009, 23, 471-484.	5.1	15
116	Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant Acinetobacter baumannii isolated from ICU patients. International Journal of Antimicrobial Agents, 2015, 45, 670-671.	2.5	15
117	Invasive fungal tracheobronchitis in mechanically ventilated critically ill patients: underlying conditions, diagnosis, and outcomes. Annals of Intensive Care, 2017, 7, 9.	4.6	15
118	Comparison of Clinical Manifestation, Diagnosis, and Outcomes of Invasive Pulmonary Aspergillosis and Pulmonary Mucormycosis. Microorganisms, 2019, 7, 531.	3.6	15
119	Clostridioides difficile (formerly Clostridium difficile) infection in the critically ill: an expert statement. Intensive Care Medicine, 2020, 46, 215-224.	8.2	15
120	Use of IFNÎ ³ /IL10 Ratio for Stratification of Hydrocortisone Therapy in Patients With Septic Shock. Frontiers in Immunology, 2021, 12, 607217.	4.8	15
121	Bloodstream infections in ICU with increased resistance: epidemiology and outcomes. Minerva Anestesiologica, 2015, 81, 405-18.	1.0	14
122	Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study. International Journal of Antimicrobial Agents, 2022, 60, 106591.	2.5	14
123	Duration of pneumonia therapy and the role of biomarkers. Current Opinion in Infectious Diseases, 2017, 30, 221-225.	3.1	13
124	Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units. Drugs, 2021, 81, 1065-1078.	10.9	13
125	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infectious Diseases and Therapy, 2022, 11, 827-840.	4.0	13
126	Understanding antibiotic stewardship for the critically ill. Intensive Care Medicine, 2016, 42, 2063-2065.	8.2	12

8

#	Article	IF	CITATIONS
127	Penicillins vs trimethoprim-based regimens for acute bacterial exacerbations of chronic bronchitis: meta-analysis of randomized controlled trials. Canadian Family Physician, 2009, 55, 60-7.	0.4	12
128	What is new in the use of aminoglycosides in critically ill patients?. Intensive Care Medicine, 2014, 40, 1553-1555.	8.2	11
129	Haplotypes composed of minor frequency single nucleotide polymorphisms of the TNF gene protect from progression into sepsis: A study using the new sepsis classification. International Journal of Infectious Diseases, 2018, 67, 102-106.	3.3	11
130	<i>Candida albicans</i> chronic colonisation in cystic fibrosis may be associated with inhaled antibiotics. Mycoses, 2015, 58, 416-421.	4.0	10
131	Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?. Expert Review of Respiratory Medicine, 2016, 10, 907-918.	2.5	10
132	<i>Scedosporium apiospermum</i> complex in cystic fibrosis; should we treat?. Mycoses, 2017, 60, 594-599.	4.0	10
133	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method. Lancet Infectious Diseases, The, 2022, 22, e74-e87.	9.1	10
134	Past history of stage I/II solid tumor malignancy impacts considerably on sepsis mortality: a propensity score matching analysis from the hellenic sepsis study group. BMC Infectious Diseases, 2019, 19, 831.	2.9	9
135	A Severe COVID-19 Case Complicated by Right Atrium Thrombus. American Journal of Case Reports, 2020, 21, e926915.	0.8	9
136	Fungal Infections in Critically Ill COVID-19 Patients: Inevitabile Malum. Journal of Clinical Medicine, 2022, 11, 2017.	2.4	9
137	In 2035, will all bacteria be multiresistant? Yes. Intensive Care Medicine, 2016, 42, 2014-2016.	8.2	8
138	Elderly versus non-elderly patients with intra-abdominal candidiasis in the ICU. Minerva Anestesiologica, 2017, 83, 1126-1136.	1.0	8
139	L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. American Journal of Case Reports, 2013, 14, 311-314.	0.8	8
140	Duration of therapy of ventilator-associated pneumonia. Current Opinion in Infectious Diseases, 2016, 29, 218-222.	3.1	7
141	Predictors of choice of initial antifungal treatment in intraabdominal candidiasis. Clinical Microbiology and Infection, 2016, 22, 719-724.	6.0	7
142	Comparative pharmacokinetics of the three echinocandins in ICU patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 2969-2976.	3.0	7
143	Invasive Pulmonary Aspergillosis in Chronic Obstructive Pulmonary Disease Exacerbations. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 851-861.	2.1	7
144	Population pharmacokinetics of anidulafungin in ICU patients assessing inter―and intrasubject variability. British Journal of Clinical Pharmacology, 2021, 87, 1024-1032.	2.4	7

#	Article	IF	CITATIONS
145	Immediate post-operative effects of tracheotomy on respiratory function during mechanical ventilation. Critical Care, 2004, 8, R243.	5.8	6
146	Post-operative Aspergillus mediastinitis in a man who was immunocompetent: a case report. Journal of Medical Case Reports, 2010, 4, 312.	0.8	6
147	"Salvage treatment―for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal. Intensive Care Medicine, 2017, 43, 1164-1166.	8.2	6
148	An overview on severe infections in Europe. Intensive Care Medicine, 2017, 43, 686-689.	8.2	6
149	Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects. Drugs, 2017, 77, 1399-1412.	10.9	6
150	Drivers and impact of antifungal therapy in critically ill patients with Aspergillus-positive respiratory tract cultures. International Journal of Antimicrobial Agents, 2017, 50, 529-535.	2.5	6
151	TB or not TB: update from the ERS Respiratory Infection Assembly 10. European Respiratory Journal, 2010, 36, 665-670.	6.7	5
152	Understanding resistance in Pseudomonas. Intensive Care Medicine, 2020, 46, 350-352.	8.2	5
153	Meta-analyses on the Prevention and Treatment of Respiratory Tract Infections. Infectious Disease Clinics of North America, 2009, 23, 331-353.	5.1	4
154	Esmolol: immunomodulator in pyelonephritis by Pseudomonas aeruginosa. Journal of Surgical Research, 2015, 198, 175-184.	1.6	4
155	Endomyocardial and pericardial aspergillosis in critically ill patients. Mycoses, 2017, 60, 576-580.	4.0	4
156	Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?. Journal of Pharmacy and Pharmacology, 2020, 72, 1750-1760.	2.4	4
157	Improving diagnostic accuracy for invasive pulmonary aspergillosis in the intensive care unit. Annals of Translational Medicine, 2016, 4, 352-352.	1.7	4
158	Characteristics, risk factors and outcomes of Clostridium difficile infections in Greek Intensive Care Units. Intensive and Critical Care Nursing, 2019, 53, 73-78.	2.9	3
159	Phenotypic/Genotypic Profile of OXA-10-Like-Harboring, Carbapenem-Resistant Pseudomonas aeruginosa: Using Validated Pharmacokinetic/Pharmacodynamic In Vivo Models To Further Evaluate Enzyme Functionality and Clinical Implications. Antimicrobial Agents and Chemotherapy, 2021, 65, e0127421.	3.2	3
160	Invasive pulmonary aspergillosis in solidâ€organ transplant patients in the intensive care unit. Transplant Infectious Disease, 2022, 24, e13746.	1.7	3
161	Reply to Rhodes et al. Clinical Infectious Diseases, 2014, 59, 907-908.	5.8	2
162	What is new in infection prevention in critical care in 2014?. Intensive Care Medicine, 2014, 40, 1151-1154.	8.2	2

#	Article	IF	CITATIONS
163	Susceptibility profiles and clinical efficacy of antifungals against candida bloodstream isolates from critically ill patients: Focus on intravenous itraconazole. International Journal of Antimicrobial Agents, 2019, 54, 471-477.	2.5	2
164	Antibiotics Selection for Bacteremic Pneumonia. Chest, 2007, 132, 360-361.	0.8	1
165	Selection for Candida Non-albicans spp. After Fluconazole Use. Anesthesia and Analgesia, 2008, 107, 2091-2092.	2.2	1
166	Re: Semirecumbent position to prevent ventilator-associated pneumonia is not evidence based. Journal of Critical Care, 2010, 25, 153-154.	2.2	1
167	ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training. Breathe, 2018, 14, 269-275.	1.3	1
168	Propofol associated Brugada – like coved type electrogardiogram in a trauma patient with a fatal outcome. Acta Cardiologica, 2019, 74, 274-275.	0.9	1
169	Infections in elderly intensive care unit patients. Journal of Emergency and Critical Care Medicine, 2019, 3, 44-44.	0.7	1
170	Post mortem examination in the intensive care unit: still useful?. Intensive Care Medicine, 2005, 31, 312-312.	8.2	0
171	Yeast central nervous system infection in a critically ill patient: a case report. Journal of Medical Case Reports, 2014, 8, 253.	0.8	0
172	Antibiotic treatment and prevention of exacerbations of COPD. , 2013, , 96-106.		0
173	Kinetics of serum adiponectin and HMWA (High Molecular Weight Adiponectin), and mortality in ICU patients with sepsis. , 2017, , .		0
174	Circulating fetuin-A as a biomarker predicting mortality in ICU septic patients. , 2017, , .		0
175	When the duration of infusion does matter: the case of meropenem and piperacillin. Minerva Anestesiologica, 2014, 80, 1258-60.	1.0	0